Strategies to increase drug penetration in solid tumors

Frontiers in Oncology

Volumn 3 JUL, Issue , 2013, Pages

  Choi, Il Kyu ^a   Strauss, Robert ^b   Richter, Maximilian ^c   Yun, Chae Ok ^a   Lieber, André ^c  

^a Hanyang University   (South Korea)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Epithelial junctions; Extracellular matrix; Junction opener; Relaxin; Tumor stroma; Tumor associated macrophages

Indexed keywords

CETUXIMAB; CLAUDIN 7; CYCLOOXYGENASE 2; DECORIN; DESMOGLEIN 2; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 1; INTERLEUKIN 8; IRINOTECAN; JO 1 ANTIBODY; LAMININ; MACROPHAGE DERIVED CHEMOKINE; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PACLITAXEL; RELAXIN; SCATTER FACTOR; SCLEROPROTEIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CELL JUNCTION; CHEMOTHERAPY; DIARRHEA; DRUG PENETRATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE TRANSFER; HUMAN; HYPOXIA; IMMUNOFLUORESCENCE; IMMUNOGENICITY; INTRACELLULAR SIGNALING; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; STROMA CELL; SURVIVAL; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84891111855     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00193     Document Type: Review

References (206)

1. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer (2001) 1(1):46-54. doi:10.1038/35094059
2. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 4(11):839-49. doi:10.1038/nrc1477
3. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature (2004) 432(7015):332-7. doi:10.1038/nature03096
4. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science (2002) 296(5570):1046-9. doi:10.1126/science.1067431
5. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development (2004) 131(23):5883-95. doi:10.1242/dev.01461
6. Rebustini IT, Myers C, Lassiter KS, Surmak A, Szabova L, Holmbeck K, et al. MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis. Dev Cell (2009) 17(4):482-93. doi:10.1016/j.devcel.2009.07.016
7. Puri S, Hebrok M. Cellular plasticity within the pancreas-lessons learned from development. Dev Cell (2010) 18(3):342-56. doi:10.1016/j.devcel.2010.02.005
8. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol (2006) 1:119-50. doi:10.1146/annurev.pathol.1.110304.100224
9. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res (2012) 18(16):4266-76. doi:10.1158/1078-0432.CCR-11-3114
10. Yun CO. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr Opin Mol Ther (2008) 10(4):356-61.
11. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 18(6):884-901. doi:10.1016/j.devcel.2010.05.012
12. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech (2011) 4(2):165-78. doi:10.1242/dmm.004077
13. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 196(4):395-406. doi:10.1083/jcb.201102147
14. Zhu GG, Risteli L, Makinen M, Risteli J, Kauppila A, Stenback F. Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms. Cancer (1995) 75(4):1010-7. doi:10.1002/1097-0142(19950215)75:4<010::AID-CNCR2820750417>3.0.CO;2-O
15. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev (1996) 76(1):69-125.
16. Kauppila S, Stenback F, Risteli J, Jukkola A, Risteli L. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol (1998) 186(3):262-8. doi:10.1002/(SICI)1096-9896(1998110)186:3<262::AID-PATH191>3.0.CO;2-3
17. Huijbers IJ, Iravani M, Popov S, Robertson D, Al-Sarraj S, Jones C, et al. A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PLoS ONE (2010) 5(3):e9808. doi:10.1371/journal.pone.0009808
18. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A (2001) 98(8):4628-33. doi:10.1073/pnas.081626898
19. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev (1990) 9(3):253-66. doi:10.1007/BF00046364
20. Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther (1999) 6(9):1520-35. doi:10.1038/sj.gt.3301030
21. Li ZY, Ni S, Yang X, Kiviat N, Lieber A. Xenograft models for liver metastasis: relationship between tumor morphology and adenovirus vector transduction. Mol Ther (2004) 9(5):650-7. doi:10.1016/j.ymthe.2004.01.021
22. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther (1999) 290(2):871-80.
23. Gorlach A, Herter P, Hentschel H, Frosch PJ, Acker H. Effects of nIFN beta and rIFN gamma on growth and morphology of two human melanoma cell lines: comparison between two-and three-dimensional culture. Int J Cancer (1994) 56(2):249-54. doi:10.1002/ijc.2910560218
24. Wenning LA, Murphy RM. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol Bioeng (1999) 62(5):562-75. doi:10.1002/(SICI)1097-0290(19990305)62:5<562::AID-BIT8>3.0.CO;2-4
25. Strauss R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D, et al. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res (2009) 69(12):5115-25. doi:10.1158/0008-5472.CAN-09-0645
26. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell (2009) 139(5):891-906. doi:10.1016/j.cell.2009.10.027
27. Lopez JI, Kang I, You WK, McDonald DM, Weaver VM. In situ force mapping of mammary gland transformation. Integr Biol (Camb) (2011) 3(9):910-21. doi:10.1039/c1ib00043h
28. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res (2000) 60(9):2497-503.
29. Brown EB, Boucher Y, Nasser S, Jain RK. Measurement of macromolecular diffusion coefficients in human tumors. Microvasc Res (2004) 67(3):231-6. doi:10.1016/j.mvr.2004.02.001
30. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer (2004) 4(10):806-13. doi:10.1038/nrc1456
31. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 121(3):335-48. doi:10.1016/j.cell.2005.02.034
32. Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem (2007) 101(4):805-15. doi:10.1002/jcb.21159
33. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol (2012) 40(6):1733-47. doi:10.3892/ijo.2012.1408
34. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer (2006) 6(5):392-401. doi:10.1038/nrc1877
35. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev (2009) 19(1):67-73. doi:10.1016/j.gde.2009.01.003
36. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res (2001) 264(1):169-84. doi:10.1006/excr.2000.5133
37. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420(6917):860-7. doi:10.1038/nature01322
38. Dean JP, Nelson PS. Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer (2008) 98(2):245-9. doi:10.1038/sj.bjc.6604087
39. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol (2003) 200(4):500-3. doi:10.1002/path.1427
40. Barsky SH, Green WR, Grotendorst GR, Liotta LA. Desmoplastic breast carcinoma as a source of human myofibroblasts. Am J Pathol (1984) 115(3):329-33.
41. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res (2010) 316(8):1324-31. doi:10.1016/j.yexcr.2010.02.045
42. De Wever O, Nguyen QD, Van Hoorde L, Bracke M, Bruyneel E, Gespach C, et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J (2004) 18(9):1016-8.
43. Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene (2003) 22(20):3162-71. doi:10.1038/sj.onc.1206455
44. Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S, Ito A. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol (2004) 92(1):47-56. doi:10.1016/j.ygyno.2003.09.012
45. Orimo A, Tomioka Y, Shimizu Y, Sato M, Oigawa S, Kamata K, et al. Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin Cancer Res (2001) 7(10):3097-105.
46. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 66(2):605-12. doi:10.1158/0008-5472.CAN-05-4005
47. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res (2000) 6(8):3282-9.
48. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer (2004) 90(11):2053-8. doi:10.1038/sj.bjc.6601705
49. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 7(3):211-7. doi:10.1016/j.ccr.2005.02.013
50. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res (2007) 67(11):5064-6. doi:10.1158/0008-5472.CAN-07-0912
51. van der Bij GJ, Oosterling SJ, Meijer S, Beelen RH, van Egmond M. The role of macrophages in tumor development. Cell Oncol (2005) 27(4):203-13.
52. Lewis C, Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol (2005) 167(3):627-35. doi:10.1016/S0002-9440(10)62038-X
53. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res (2002) 62(23):7042-9.
54. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 4(1):71-8. doi:10.1038/nrc1256
55. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 11(10):889-96. doi:10.1038/ni.1937
56. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9(3):162-74. doi:10.1038/nri2506
57. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res (2010) 70(14):5728-39. doi:10.1158/0008-5472.CAN-09-4672
58. Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer (2012) 12:35. doi:10.1186/1471-2407-12-35
59. Jinushi M, Baghdadi M, Chiba S, Yoshiyama H. Regulation of cancer stem cell activities by tumor-associated macrophages. Am J Cancer Res (2012) 2(5):529-39.
60. Eck M, Schmausser B, Scheller K, Brandlein S, Muller-Hermelink HK. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol (2003) 134(3):508-15. doi:10.1111/j.1365-2249.2003.02305.x
61. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol (2009) 27(28):4709-17. doi:10.1200/JCO.2008.18.9498
62. Wislez M, Rabbe N, Marchal J, Milleron B, Crestani B, Mayaud C, et al. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res (2003) 63(6):1405-12.
63. Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol (1998) 152(1):83-92.
64. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res (2001) 61(12):4756-60.
65. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 65(1-2):271-84. doi:10.1016/S0168-3659(99)00248-5
66. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today (2006) 11(17-18):812-8. doi:10.1016/j.drudis.2006.07.005
67. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev (1997) 26(2-3):71-90. doi:10.1016/S0169-409X(97)00027-6
68. Milosevic MF, Fyles AW, Wong R, Pintilie M, Kavanagh MC, Levin W, et al. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer (1998) 82(12):2418-26. doi:10.1002/(SICI)1097-0142(19980615)82:12<2418::AID-CNCR16>3.0.CO;2-S
69. Patan S, Munn LL, Jain RK. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res (1996) 51(2):260-72. doi:10.1006/mvre.1996.0025
70. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature (2004) 427(6976):695. doi:10.1038/427695a
71. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res (2007) 67(6):2729-35. doi:10.1158/0008-5472.CAN-06-4102
72. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res (1990) 50(15):4478-84.
73. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 4(11):891-9. doi:10.1038/nrc1478
74. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res (1989) 37(1):77-104. doi:10.1016/0026-2862(89)90074-5
75. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res (1990) 40(2):246-63. doi:10.1016/0026-2862(90)90023-K
76. Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release (2001) 74(1-3):7-25. doi:10.1016/S0168-3659(01)00306-6
77. Sevick EM, Jain RK. Effect of red blood cell rigidity on tumor blood flow: increase in viscous resistance during hyperglycemia. Cancer Res (1991) 51(10):2727-30.
78. Znati CA, Rosenstein M, Boucher Y, Epperly MW, Bloomer WD, Jain RK. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res (1996) 56(5):964-8.
79. Casazza A, Di Conza G, Wenes M, Finisguerra V, Deschoemaeker S, Mazzone M. Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene (2013). doi:10.1038/onc.2013.121. [Epub ahead of print].
80. Madara JL. Regulation of the movement of solutes across tight junctions. Annu Rev Physiol (1998) 60:143-59. doi:10.1146/annurev.physiol.60.1.143
81. Turksen K, Troy TC. Barriers built on claudins. J Cell Sci (2004) 117(Pt 12):2435-47. doi:10.1242/jcs.01235
82. Sasaki H. Freeze-fracture analysis of renal-epithelial tight junctions. Methods Mol Med (2003) 86:155-66.
83. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol (1993) 123(6 Pt 2):1777-88. doi:10.1083/jcb.123.6.1777
84. Liu Y, Nusrat A, Schnell FJ, Reaves TA, Walsh S, Pochet M, et al. Human junction adhesion molecule regulates tight junction resealing in epithelia. J Cell Sci (2000) 113(Pt 13):2363-74.
85. Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci U S A (2001) 98(26):15191-6. doi:10.1073/pnas.261452898
86. Ikenouchi J, Furuse M, Furuse K, Sasaki H, Tsukita S. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J Cell Biol (2005) 171(6):939-45. doi:10.1083/jcb.200510043
87. Capaldo CT, Macara IG. Depletion of E-cadherin disrupts establishment but not maintenance of cell junctions in Madin-Darby canine kidney epithelial cells. Mol Biol Cell (2007) 18(1):189-200. doi:10.1091/mbc.E06-05-0471
88. Bryant DM, Wylie FG, Stow JL. Regulation of endocytosis, nuclear translocation, and signaling of fibroblast growth factor receptor 1 by E-cadherin. Mol Biol Cell (2005) 16(1):14-23. doi:10.1091/mbc.E04-09-0845
89. Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J (2004) 23(8):1739-48. doi:10.1038/sj.emboj.7600136
90. Perrais M, Chen X, Perez-Moreno M, Gumbiner BM. E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol Biol Cell (2007) 18(6):2013-25. doi:10.1091/mbc.E06-04-0348
91. Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science (2002) 296(5573):1644-6. doi:10.1126/science.1071549
92. Soto E, Yanagisawa M, Marlow LA, Copland JA, Perez EA, Anastasiadis PZ. p120 Catenin induces opposing effects on tumor cell growth depending on E-cadherin expression. J Cell Biol (2008) 183(4):737-49. doi:10.1083/jcb.200805113
93. Perez-Moreno M, Song W, Pasolli HA, Williams SE, Fuchs E. Loss of p120 catenin and links to mitotic alterations, inflammation, and skin cancer. Proc Natl Acad Sci U S A (2008) 105(40):15399-404. doi:10.1073/pnas.0807301105
94. Biedermann K, Vogelsang H, Becker I, Plaschke S, Siewert JR, Hofler H, et al. Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J Pathol (2005) 207(2):199-206. doi:10.1002/path.1821
95. Harada H, Iwatsuki K, Ohtsuka M, Han GW, Kaneko F. Abnormal desmoglein expression by squamous cell carcinoma cells. Acta Derm Venereol (1996) 76(6):417-20.
96. Chen J, Nekrasova OE, Patel DM, Klessner JL, Godsel LM, Koetsier JL, et al. The C-terminal unique region of desmoglein 2 inhibits its internalization via tail-tail interactions. J Cell Biol (2012) 199(4):699-711. doi:10.1083/jcb.201202105
97. Nava P, Laukoetter MG, Hopkins AM, Laur O, Gerner-Smidt K, Green KJ, et al. Desmoglein-2: a novel regulator of apoptosis in the intestinal epithelium. Mol Biol Cell (2007) 18(11):4565-78. doi:10.1091/mbc.E07-05-0426
98. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 46(1-3):3-26. doi:10.1016/S0169-409X(00)00129-0
99. Lavin SR, McWhorter TJ, Karasov WH. Mechanistic bases for differences in passive absorption. J Exp Biol (2007) 210(Pt 15):2754-64. doi:10.1242/jeb.006114
100. Green SK, Karlsson MC, Ravetch JV, Kerbel RS. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res (2002) 62(23):6891-900.
101. Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat (2009) 118(1):113-24. doi:10.1007/s10549-009-0412-3
102. Oliveras-Ferraros C, Vazquez-Martin A, Cufi S, Queralt B, Baez L, Guardeno R, et al. Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux) efficacy in KRAS wild-type tumor cells. J Cell Biochem (2011) 112(1):10-29. doi:10.1002/jcb.22952
103. Lee CM, Tannock IF. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer (2010) 10:255. doi:10.1186/1471-2407-10-255
104. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res (2006) 66(17):8319-26. doi:10.1158/0008-5472.CAN-06-0410
105. Shelly M, Mosesson Y, Citri A, Lavi S, Zwang Y, Melamed-Book N, et al. Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. Dev Cell (2003) 5(3):475-86. doi:10.1016/j.devcel.2003.08.001
106. Toledo C, Matus CE, Barraza X, Arroyo P, Ehrenfeld P, Figueroa CD, et al. Expression of HER2 and bradykinin B(1) receptors in precursor lesions of gallbladder carcinoma. World J Gastroenterol (2012) 18(11):1208-15. doi:10.3748/wjg.v18.i11.1208
107. Tong WM, Ellinger A, Sheinin Y, Cross HS. Epidermal growth factor receptor expression in primary cultured human colorectal carcinoma cells. Br J Cancer (1998) 77(11):1792-8. doi:10.1038/bjc.1998.298
108. Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J, et al. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature (2003) 422(6929):322-6. doi:10.1038/nature01440
109. Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, et al. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res (2011) 71(22):7080-90. doi:10.1158/0008-5472.CAN-11-2009
110. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell (2009) 139(5):871-90. doi:10.1016/j.cell.2009.11.007
111. Wong AS, Auersperg N. Normal ovarian surface epithelium. Cancer Treat Res (2002) 107:161-83.
112. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer (2005) 5(9):744-9. doi:10.1038/nrc1694
113. Come C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, et al. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res (2006) 12(18):5395-402. doi:10.1158/1078-0432.CCR-06-0478
114. Arnoux V, Come C, Kusewitt D, Hudson L, Savagner P. Cutaneous wound reepithelization: a partial and reversible EMT. In: Savagner P, editor. Rise and Fall of Epithelial Phenotype: Concepts of Epithelial-Mesenchymal Transition. Berlin: Springer (2005). p. 111-34.
115. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 119(6):1420-8. doi:10.1172/JCI39104
116. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta (1994) 1198(1):11-26.
117. Sabbah M, Emami S, Redeuilh G, Julien S, Prevost G, Zimber A, et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat (2008) 11(4-5):123-51. doi:10.1016/j.drup.2008.07.001
118. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol (2002) 3(3):155-66. doi:10.1038/nrm757
119. Leptin M. Twist and snail as positive and negative regulators during Drosophila mesoderm development. Genes Dev (1991) 5(9):1568-76. doi:10.1101/gad.5.9.1568
120. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol (2000) 2(2):84-9. doi:10.1038/35000034
121. Postigo AA, Depp JL, Taylor JJ, Kroll KL. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J (2003) 22(10):2453-62. doi:10.1093/emboj/cdg226
122. Ellenberger T, Fass D, Arnaud M, Harrison SC. Crystal structure of transcription factor E47: E-box recognition by a basic region helix-loop-helix dimer. Genes Dev (1994) 8(8):970-80. doi:10.1101/gad.8.8.970
123. Ikenouchi J, Matsuda M, Furuse M, Tsukita S. Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J Cell Sci (2003) 116(Pt 10):1959-67. doi:10.1242/jcs.00389
124. Ohkubo T, Ozawa M. The transcription factor Snail downregulates the tight junction components independently of E-cadherin downregulation. J Cell Sci (2004) 117(Pt 9):1675-85. doi:10.1242/jcs.01004
125. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res (2005) 33(20):6566-78. doi:10.1093/nar/gki965
126. Martinez-Estrada OM, Culleres A, Soriano FX, Peinado H, Bolos V, Martinez FO, et al. The transcription factors Slug and Snail act as repressors of claudin-1 expression in epithelial cells. Biochem J (2006) 394(Pt 2):449-57. doi:10.1042/BJ20050591
127. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 117(7):927-39. doi:10.1016/j.cell.2004.06.006
128. Perez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F, Nieto MA, et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem (2001) 276(29):27424-31. doi:10.1074/jbc.M100827200
129. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 2(6):442-54. doi:10.1038/nrc822
130. Panorchan P, Thompson MS, Davis KJ, Tseng Y, Konstantopoulos K, Wirtz D. Single-molecule analysis of cadherin-mediated cell-cell adhesion. J Cell Sci (2006) 119(Pt 1):66-74. doi:10.1242/jcs.02719
131. Janmey PA, Euteneuer U, Traub P, Schliwa M. Viscoelastic properties of vimentin compared with other filamentous biopolymer networks. J Cell Biol (1991) 113(1):155-60. doi:10.1083/jcb.113.1.155
132. Wagner OI, Rammensee S, Korde N, Wen Q, Leterrier JF, Janmey PA. Softness, strength and self-repair in intermediate filament networks. Exp Cell Res (2007) 313(10):2228-35. doi:10.1016/j.yexcr.2007.04.025
133. LaGamba D, Nawshad A, Hay ED. Microarray analysis of gene expression during epithelial-mesenchymal transformation. Dev Dyn (2005) 234(1):132-42. doi:10.1002/dvdy.20489
134. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A (2001) 98(18):10356-61. doi:10.1073/pnas.171610498
135. Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS ONE (2011) 6(1):e16186. doi:10.1371/journal.pone.0016186
136. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 8(10):755-68. doi:10.1038/nrc2499
137. Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller M. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med (2008) 8(8):784-804. doi:10.2174/156652408786733667
138. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 339(6119):580-4. doi:10.1126/science.1228522
139. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell (2012) 22(6):725-36. doi:10.1016/j.ccr.2012.09.022
140. Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell (2012) 22(6):709-24. doi:10.1016/j.ccr.2012.10.012
141. Saito T, Nagai M, Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res (2006) 66(14):6919-27. doi:10.1158/0008-5472.CAN-05-3697
142. Fitzgerald MP, Gourronc F, Teoh ML, Provenzano MJ, Case AJ, Martin JA, et al. Human chondrosarcoma cells acquire an epithelial-like gene expression pattern via an epigenetic switch: evidence for mesenchymal-epithelial transition during sarcomagenesis. Sarcoma (2011) 2011:598218. doi:10.1155/2011/598218
143. Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol (2010) 22(5):697-706. doi:10.1016/j.ceb.2010.08.015
144. Bjorge L, Junnikkala S, Kristoffersen EK, Hakulinen J, Matre R, Meri S. Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis. Br J Cancer (1997) 75(9):1247-55. doi:10.1038/bjc.1997.213
145. Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med (2003) 9(6):796-800. doi:10.1038/nm879
146. Eikenes L, Tufto I, Schnell EA, Bjorkoy A, De Lange Davies C. Effect of collagenase and hyaluronidase on free and anomalous diffusion in multicellular spheroids and xenografts. Anticancer Res (2010) 30(2):359-68.
147. Kuriyama N, Kuriyama H, Julin CM, Lamborn K, Israel MA. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther (2000) 11(16):2219-30. doi:10.1089/104303400750035744
148. McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res (2006) 66(5):2509-13. doi:10.1158/0008-5472.CAN-05-2242
149. Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M, Jooss K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res (2008) 14(12):3933-41. doi:10.1158/1078-0432.CCR-07-4732
150. Cheng J, Sauthoff H, Huang Y, Kutler DI, Bajwa S, Rom WN, et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther (2007) 15(11):1982-90. doi:10.1038/sj.mt.6300264
151. Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and-8 improve the distribution and efficacy of an oncolytic virus. Cancer Res (2007) 67(22):10664-8. doi:10.1158/0008-5472.CAN-07-3107
152. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol (1996) 3(11):895-904. doi:10.1016/S1074-5521(96)90178-7
153. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 141(1):52-67. doi:10.1016/j.cell.2010.03.015
154. Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M, et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res (2007) 67(9):4399-407. doi:10.1158/0008-5472.CAN-06-4260
155. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst (2006) 98(20):1482-93. doi:10.1093/jnci/djj397
156. Beyer I, Li Z, Persson J, Liu Y, van Rensburg R, Yumul R, et al. Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther (2011) 19(3):479-89. doi:10.1038/mt.2010.256
157. Li Z, Liu Y, Tuve S, Xun Y, Fan X, Min L, et al. Toward a stem cell gene therapy for breast cancer. Blood (2009) 113(22):5423-33. doi:10.1182/blood-2008-10-187237
158. Choi IK, Lee YS, Yoo JY, Yoon AR, Kim H, Kim DS, et al. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther (2010) 17(2):190-201. doi:10.1038/gt.2009.142
159. Dschietzig T, Bartsch C, Baumann G, Stangl K. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther (2006) 112(1):38-56. doi:10.1016/j.pharmthera.2006.03.004
160. Sherwood OD. Relaxin's physiological roles and other diverse actions. Endocr Rev (2004) 25(2):205-34. doi:10.1210/er.2003-0013
161. Van Der Westhuizen ET, Summers RJ, Halls ML, Bathgate RA, Sexton PM. Relaxin receptors-new drug targets for multiple disease states. Curr Drug Targets (2007) 8(1):91-104. doi:10.2174/138945007779315650
162. Amento EP, Bhan AK, McCullagh KG, Krane SM. Influences of gamma interferon on synovial fibroblast-like cells. Ia induction and inhibition of collagen synthesis. J Clin Invest (1985) 76(2):837-48. doi:10.1172/JCI112041
163. Bathgate RA, Lekgabe ED, McGuane JT, Su Y, Pham T, Ferraro T, et al. Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis. Mol Cell Endocrinol (2008) 280(1-2):30-8. doi:10.1016/j.mce.2007.09.008
164. Cernaro V, Lacquaniti A, Lupica R, Buemi A, Trimboli D, Giorgianni G, et al. Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein. Med Res Rev (2013). doi:10.1002/med.21277. [Epub ahead of print].
165. Silvertown JD, Ng J, Sato T, Summerlee AJ, Medin JA. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer (2006) 118(1):62-73. doi:10.1002/ijc.21288
166. Silvecrtown JD, Symes JC, Neschadim A, Nonaka T, Kao JC, Summerlee AJ, et al. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J (2007) 21(3):754-65. doi:10.1096/fj.06-6847com
167. Binder C, Hagemann T, Husen B, Schulz M, Einspanier A. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Mol Hum Reprod (2002) 8(9):789-96. doi:10.1093/molehr/8.9.789
168. Radestock Y, Hoang-Vu C, Hombach-Klonisch S. Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells. Breast Cancer Res (2008) 10(4):R71. doi:10.1186/bcr2136
169. Vogel KG, Paulsson M, Heinegard D. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J (1984) 223(3):587-97.
170. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature (1990) 346(6281):281-4. doi:10.1038/346281a0
171. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol (1997) 136(3):729-43. doi:10.1083/jcb.136.3.729
172. Wei H, Liu P, Swisher E, Yip YY, Tse JH, Agnew K, et al. Silencing of the TGF-beta1 gene increases the immunogenicity of cells from human ovarian carcinoma. J Immunother (2012) 35(3):267-75. doi:10.1097/CJI.0b013e31824d72ee
173. Sonoda N, Furuse M, Sasaki H, Yonemura S, Katahira J, Horiguchi Y, et al. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J Cell Biol (1999) 147(1):195-204. doi:10.1083/jcb.147.1.195
174. Fasano A, Baudry B, Pumplin DW, Wasserman SS, Tall BD, Ketley JM, et al. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci U S A (1991) 88(12):5242-6. doi:10.1073/pnas.88.12.5242
175. Cox DS, Raje S, Gao H, Salama NN, Eddington ND. Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin. Pharm Res (2002) 19(11):1680-8. doi:10.1023/A:1020709513562
176. Latorre IJ, Roh MH, Frese KK, Weiss RS, Margolis B, Javier RT. Viral oncoprotein-induced mislocalization of select PDZ proteins disrupts tight junctions and causes polarity defects in epithelial cells. J Cell Sci (2005) 118(Pt ) 18):4283-93. doi:10.1242/jcs.02560
177. Walters RW, Freimuth P, Moninger TO, Ganske I, Zabner J, Welsh MJ. Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell (2002) 110(6):789-99. doi:10.1016/S0092-8674(02)00912-1
178. Coyne CB, Shen L, Turner JR, Bergelson JM. Coxsackievirus entry across epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5. Cell Host Microbe (2007) 2(3):181-92. doi:10.1016/j.chom.2007.07.003
179. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VH, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature (2011) 480(7378):530-3. doi:10.1038/nature10639
180. Aungst BJ. Intestinal permeation enhancers. J Pharm Sci (2000) 89(4):429-42. doi:10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
181. Wang H, Li ZY, Liu Y, Persson J, Beyer I, Moller T, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2011) 17(1):96-104. doi:10.1038/nm.2270
182. Wang H, Li Z, Yumul R, Lara S, Hemminki A, Fender P, et al. Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. J Virol (2011) 85(13):6390-402. doi:10.1128/JVI.00514-11
183. Beyer I, Cao H, Persson J, Song H, Richter M, Feng Q, et al. Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin Cancer Res (2012) 18(12):3340-51. doi:10.1158/1078-0432.CCR-11-3213
184. Su YC, Chen BM, Chuang KH, Cheng TL, Roffler SR. Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjug Chem (2010) 21(7):1264-70. doi:10.1021/bc100067t
185. Wang H, Beyer I, Persson J, Song H, Li Z, Richter M, et al. A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses. J Virol (2012) 86(11):6286-302. doi:10.1128/JVI.00205-12
186. Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol (2007) 39(12):2153-60. doi:10.1016/j.biocel.2007.07.011
187. Dhar D, Spencer JF, Toth K, Wold WS. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther (2009) 17(10):1724-32. doi:10.1038/mt.2009.156
188. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther (2008) 16(10):1665-73. doi:10.1038/mt.2008.162
189. Bouvet M, Fang B, Ekmekcioglu S, Ji L, Bucana CD, Hamada K, et al. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther (1998) 5(2):189-95. doi:10.1038/sj.gt.3300564
190. Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res (2005) 65(24):11743-51. doi:10.1158/0008-5472.CAN-05-0045
191. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 6(4):295-307. doi:10.1038/nri1806
192. Kimura YN, Watari K, Fotovati A, Hosoi F, Yasumoto K, Izumi H, et al. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci (2007) 98(12):2009-18. doi:10.1111/j.1349-7006.2007.00633.x
193. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest (2006) 116(8):2132-41. doi:10.1172/JCI27648
194. Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M, et al. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer (2009) 125(6):1276-84. doi:10.1002/ijc.24378
195. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer (2006) 95(3):272-81. doi:10.1038/sj.bjc.6603240
196. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2013) 73(3):1128-41. doi:10.1158/0008-5472.CAN-12-2731
197. Aboody KS, Najbauer J, Metz MZ, D'Apuzzo M, Gutova M, Annala AJ, et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med (2013) 5(184):184ra59. doi:10.1126/scitranslmed.3005365
198. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther (2005) 315(3):971-9. doi:10.1124/jpet.105.084145
199. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 361(10):947-57. doi:10.1056/NEJMoa0810699
200. Chua KN, Sim WJ, Racine V, Lee SY, Goh BC, Thiery JP. A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. PLoS ONE (2012) 7(3):e33183. doi:10.1371/journal.pone.0033183
201. Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther (2010) 9(12):3221-32. doi:10.1158/1535-7163.MCT-10-0570
202. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest (2002) 110(10):1525-38. doi:10.1172/JCI200216219
203. Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S, et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med (2011) 208(13):2641-55. doi:10.1084/jem.20110840
204. Qi L, Sun B, Liu Z, Li H, Gao J, Leng X. Dickkopf-1 inhibits epithelial-mesenchymal transition of colon cancer cells and contributes to colon cancer suppression. Cancer Sci (2012) 103(4):828-35. doi:10.1111/j.1349-7006.2012.02222.x
205. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 145(6):926-40. doi:10.1016/j.cell.2011.04.029
206. Strauss R, Sova P, Liu Y, Li Z-Y, Tuve S, Pritchard D, et al. Epithelial phenotype of ovarian cancer mediates resistance to oncolytic adenoviruses. Cancer Res (2009) 15(69):5115-25. doi:10.1158/0008-5472.CAN-09-0645